Wall Street analyst estimates for Incannex Healthcare Limited (IXHL): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Incannex Healthcare Limited is an Australian company dedicated to the research, development, and commercialization of medicinal cannabinoid products. The firm offers pharmaceutical-grade cannabinoid compounds under its proprietary Incannex brand. Its product pipeline includes several key assets: IHL-42X: This compound is currently undergoing Phase II clinical evaluation for the treatment of obstructive sleep apnea (OSA).
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-13 | $-0.01 | ||
| 2026-09-17 | $0.13 | ||
| 2026-05-15 | $-0.35 | $-0.60 | +41.7% |
| 2026-02-13 | $-0.60 | $-0.60 | +0.0% |
| 2025-11-14 | $-0.60 | $-11.70 | +94.9% |
| 2025-09-29 | $-0.57 | $-0.00 | -19451.7% |
| 2025-05-15 | $-7.21 | $-13.81 | +47.8% |
| 2025-02-14 | $-9.91 | $-13.20 | +24.9% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $91688 | $283015 | $1.0M | $1.2M | $599722 | $1.9M | $785151 | 0 | $12000 | $86000 |
| Cost of Revenue | $303331 | $518275 | $522833 | $583188 | $446502 | $913257 | $6335 | 0 | $103000 | $246000 |
| Gross Profit | -$213893 | -$235260 | $486993 | $597260 | $153219 | $987019 | $778790 | 0 | $12000 | -$160000 |
| Research & Development | 0 | 0 | 0 | 0 | 0 | $4.8M | $5.4M | $9.5M | $19.3M | $10.7M |
| Selling, General & Admin | $514057 | $2.7M | $3.6M | $2.6M | $2.2M | $7.7M | $10.2M | $11.9M | $25.6M | $13.1M |
| Operating Expenses | $506474 | $20.8M | $3.7M | $3.4M | $4.3M | $12.4M | $12.1M | $20.5M | $30.1M | $23.6M |
| Operating Income | -$658053 | -$21.0M | -$3.2M | -$2.8M | -$4.1M | -$11.4M | -$11.4M | -$20.5M | -$30.0M | -$23.8M |
| EBITDA | -$704753 | -$21.0M | -$3.1M | -$2.7M | -$4.1M | -$11.3M | -$16.5M | -$20.4M | -$27.7M | -$23.5M |
| Interest Expense | $81501 | $49972 | $12852 | $85207 | 0 | 0 | 0 | 0 | 0 | $303000 |
| Pre-tax Income | -$738047 | -$21.1M | -$3.2M | -$2.9M | -$3.9M | -$11.4M | -$14.9M | -$73.5M | -$18.4M | -$48.6M |
| Income Tax | 0 | -$305756 | -$262652 | -$151577 | 0 | 0 | 0 | 0 | $30000 | -$1.8M |
| Net Income | -$719931 | -$20.8M | -$2.9M | -$2.7M | -$4.7M | -$11.4M | -$14.9M | -$73.5M | -$18.5M | -$46.9M |
| EPS | $-1.41 | $-19.59 | $-1.56 | $-0.74 | $-0.69 | $-1.40 | $-1.50 | $-14.31 | $-3.42 | $-40.80 |
| EPS (Diluted) | $-1.41 | $-19.59 | $-1.56 | $-0.74 | $-0.69 | $-1.40 | $-1.50 | $-14.31 | $-3.42 | $-40.80 |
| Shares Outstanding (Diluted) | $522931 | $1.1M | $1.9M | $3.7M | $5.7M | $8.2M | $9.9M | $5.1M | $5.4M | $1.1M |
Price
| Price | $3.80 |
| Market Cap | $45M |
| Exchange | NASDAQ |
| Country | AU |
Related companies: AGEN · CGTX · IRD · LUCD · SCLX · SEER · STSS
Explore sector: Healthcare · Biotechnology
More sections of IXHL: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks